← Leaderboards
Jacob S Bowers
Medical University Of South Carolina
$181,784
Attributed
$181,784
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $46.2K · FY2015–18$50K$37.5K$25K$12.5K$0
'15
'16
'17
'18
Funding mix
By agency
NIH$181,784 · 1
By mechanism
F30$181,784 · 1
Top collaborators
No co-investigators on record.
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Shikhar Mehrotra$11,720,155
- Sophie Paczesny$15,189,813
- Chrystal Mary Paulos$6,163,426
- Besim Ogretmen$19,638,711
- Gary S. Gilkeson$15,374,032
Others in their field
Top investigators on “Affect”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$287,585,588
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$209,385,844
- David Heimbrook · Leidos Biomedical Research, Inc.$168,138,264
- Daniel R Kuritzkes · Brigham And Women'S Hospital$151,687,019
Research focus
AffectFutureApoptosisApoptoticAntitumor ResponseEngraftmentBloodCancer ImmunotherapyCancer PatientCancer TherapyBaseCd4 Positive T LymphocytesBiological PreservationAdoptive TransferCellsCell TransformationChimeric Antigen ReceptorClinically RelevantClinical TrialsConduct Clinical TrialsCytotoxicDisease RemissionDoseGenetic Engineering
Grant awards (4)
Defining and translating the properties that sustain the antitumor efficacy of Th17 cells$46,154
F30 · FY2018 · CA · contact PI
Defining and translating the properties that sustain the antitumor efficacy of Th17 cells$45,674
F30 · FY2017 · CA · contact PI
Defining and translating the properties that sustain the antitumor efficacy of Th17 cells$45,206
F30 · FY2016 · CA · contact PI
Defining and translating the properties that sustain the antitumor efficacy of Th17 cells$44,750
F30 · FY2015 · CA · contact PI